Soluble concentrations of the terminal complement complex C5b-9 correlate with end-organ injury in preeclampsia

•We evaluated soluble C5b-9 levels in women with hypertensive disorders of pregnancy.•Plasma C5b-9 levels were lowest in patients with hypertension and end-organ injury.•Urine C5b-9 levels were highest in patients with hypertension and end-organ injury.•C5b-9 levels may help identify complement-medi...

Full description

Saved in:
Bibliographic Details
Published in:Pregnancy hypertension 2022-08, Vol.29, p.92-97
Main Authors: Valencia, Catalina M., Hersh, Alyssa R., Burwick, Richard M., Velásquez, Jesús A., Gutiérrez-Marín, Jorge, Edna, Francisco, Silva, Jaime L., Trujillo-Otálvaro, Juliana, Vargas-Rodríguez, Johanna, Bernal, Yamile, Quintero, Alvaro, Rincón, Mónica, Tolosa, Jorge E.
Format: Article
Language:English
Subjects:
Complement membrane attack complex
Complement system proteins
Hypertension
Preeclampsia
Pregnancy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We evaluated soluble C5b-9 levels in women with hypertensive disorders of pregnancy.•Plasma C5b-9 levels were lowest in patients with hypertension and end-organ injury.•Urine C5b-9 levels were highest in patients with hypertension and end-organ injury.•C5b-9 levels may help identify complement-mediated end-organ injury in preeclampsia. We sought to determine if soluble levels of C5b-9, the terminal complement complex, correlate with end-organ injury in preeclampsia. Project COPA (Complement and Preeclampsia in the Americas), a multi-center observational study in Colombia from 2015 to 2016, enrolled hypertensive pregnant women into four groups: chronic hypertension, gestational hypertension, preeclampsia, and preeclampsia with severe features. Trained coordinators collected clinical data, blood and urine. End-organ injury was defined by serum creatinine ≥ 1.0 mg/dl, aspartate transaminase ≥ 70U/L, platelet count 
ISSN:2210-7789
2210-7797
DOI:10.1016/j.preghy.2022.07.001